secwatch.observer — SEC 8-K summary
======================================

Issuer:     Q/C TECHNOLOGIES, INC. (QCLS)
CIK:        0001321834
Form:       8-K
Filed at:   2023-08-03T23:59:59+00:00
Accession:  0001493152-23-026626
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MyMD discusses Phase 2 results for MYMD-1 in sarcopenia/frailty; transcript furnished without specific data
--------------------------------------------------------------------------------

- Conference call held August 2, 2023 to discuss Phase 2 results of oral TNF-α inhibitor MYMD-1.
- Indication: chronic inflammation associated with sarcopenia (age-related frailty).
- Transcript furnished as Exhibit 99.1 but appended text does not contain quantitative results.
- Participants included Chairman Josh Silverman, President Chris Chapman, and CSO Adam Kaplin.
- No safety or efficacy endpoints, trial sizes, or statistical outcomes disclosed in the provided exhibit excerpt.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1321834/000149315223026626/0001493152-23-026626-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1321834/000149315223026626/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-026626

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer